As at Jun 25, 2025, the PBYI stock has a price-to-earnings ratio of 4.3. This is based on the current EPS of $0.77 and the stock price of $3.31 per share. A decrease of 45% has been recorded in the PE ratio compared to the average of 7.8 of the last four quarters.
The mean historical PE ratio of Puma Biotechnology over the last three years is 15.1. The current 4.3 P/E ratio is 72% lower than the historical average. In the past three years, PBYI's PE ratio peaked in the Sep 2023 quarter at 37.57, with a price of $2.63 and an EPS of $0.07. The Mar 2025 quarter marked the lowest point at 3.84, with a price of $2.96 and an EPS of $0.77.
Maximum annual decrease: -47.72% in 2024
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | 4.92 | -47.72% | $3.05 | $0.62 |
2023 | 9.41 | N/A | $4.33 | $0.46 |
2022 | N/A | N/A | $4.23 | $0 |
2021 | N/A | N/A | $3.04 | -$0.72 |
2020 | N/A | N/A | $10.26 | -$1.52 |
2019 | N/A | N/A | $8.75 | -$1.95 |
2018 | N/A | N/A | $20.35 | -$2.99 |
2017 | N/A | N/A | $98.85 | -$7.85 |
2016 | N/A | N/A | $30.7 | -$8.29 |
2015 | N/A | N/A | $78.4 | -$7.45 |
2014 | N/A | N/A | $189.27 | -$4.73 |
2013 | N/A | N/A | $103.53 | -$1.9 |
2012 | N/A | N/A | $18.75 | -$3.42 |
2011 | N/A | N/A | N/A | -$1.32 |
2010 | N/A | N/A | N/A | $0 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Mar 2025 | 3.84 | -21.95% | $2.96 | $0.77 |
Dec 2024 | 4.92 | -7.34% | $3.05 | $0.62 |
Sep 2024 | 5.31 | -69.06% | $2.55 | $0.48 |
Jun 2024 | 17.16 | 6.85% | $3.26 | $0.19 |
Mar 2024 | 16.06 | 70.67% | $5.3 | $0.33 |
Dec 2023 | 9.41 | -74.95% | $4.33 | $0.46 |
Sep 2023 | 37.57 | N/A | $2.63 | $0.07 |
Jun 2023 | N/A | N/A | $3.53 | -$0.06 |
Mar 2023 | 30.9 | N/A | $3.09 | $0.1 |
Dec 2022 | N/A | N/A | $4.23 | $0 |
Sep 2022 | 10.77 | N/A | $2.37 | $0.22 |
Jun 2022 | N/A | N/A | $2.85 | -$0.86 |
Mar 2022 | N/A | N/A | $2.88 | -$1.2 |
Dec 2021 | N/A | N/A | $3.04 | -$0.72 |
Sep 2021 | N/A | N/A | $7.01 | -$1.19 |
The current PE ratio of PBYI is lower than the 3, 5 and 10-year averages.
In comparison to its peer stock PFE, PBYI's PE ratio is lower.
Stock name | PE ratio | Market cap |
---|---|---|
PBYI Puma Biotechnology Inc | 4.3 | $164.3M |
PFE Pfizer Inc | 17.45 | $137.93B |
ARRY Array Technologies Inc | N/A | $951.89M |
The price to earnings ratio for PBYI stock is 4.3 as of Jun 25, 2025.
Over the last 3 years, the average price to earnings ratio for PBYI stock is 15.1.
Over the last 5 years, the average price to earnings ratio for PBYI stock is 15.1.
The highest quarterly PE ratio in the last three years has been 37.57 and it was in the Sep 2023 quarter.
PBYI's current price to earnings ratio is 72% below its 3-year historical average.
PBYI's PE ratio of 4.3 is considered low because the company's stock price is trading at a lower multiple of earnings.
The P/E ratio is obtained by dividing the latest price of a stock by its trailing twelve months EPS. As of today (Jun 25, 2025), Puma Biotechnology's stock price is $3.31. The earnings per share for the trailing twelve months (TTM) ending Mar 2025 is $0.77. Therefore, Puma Biotechnology's PE ratio for today is 4.3. PE RATIO(4.3) = STOCK PRICE($3.31) / TTM EPS($0.77)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.